COVID-19 Pneumonia Clinical Trial
Official title:
Safety and Efficacy and of Ivermectin for the Prevention of Severe Disease in Patients With COVID-19: A Randomized, Controlled, Double-Blind Clinical Study.
A parallel, prospective, double-blind, placebo-controlled clinical trial will be conducted in the population affiliated to EPS SURAMERICANA S.A. with positive test for antigen and PCR for SARS-CoV-2. Participants will be randomly assigned in a 1: 1 ratio to the intervention group or the control group using a sequence of random numbers. The patients included will be those with less than 7 days from the onset of symptoms, and without evidence of serious disease. One group will be assigned oral ivermectin therapy at a dose of 600 mcg/kg every 12 hours for 5 consecutive days, and the other group will received placebo. A minimum sample size of 483 patients for each arm was calculated to observe differences. All randomized patients will be included in the analysis according to the randomization arm (intention-to-treat analysis). The primary objective is to evaluate the efficacy of ivermectin in the prevention of severe disease, reduction in the rate of hospitalization, reduction of ICU stay, and mortality. This evaluation will be carried out up to 28 days after the intervention begins. Given the public health emergency, the study is expected to be completed in a period of 6 months from the INVIMA approval.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Suspended |
NCT04901676 -
Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia
|
Phase 3 | |
| Not yet recruiting |
NCT04534478 -
Oral Prednisone Regimens to Optimize the Therapeutic Strategy in Patients With Organizing Pneumonia Post-COVID-19
|
Phase 4 | |
| Active, not recruiting |
NCT05002517 -
Randomized, Unicentric, Open, Controlled Clinical Trial, in Phase Iii, to Demonstrate the Effectiveness of Tocilizumab
|
Phase 3 | |
| Completed |
NCT05008393 -
Efficacy of PJS-539 for Adult Patients With COVID-19.
|
Phase 2 | |
| Completed |
NCT04569877 -
GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia
|
Phase 2 | |
| Not yet recruiting |
NCT05286255 -
Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias
|
Phase 1 | |
| Completed |
NCT05035589 -
The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia
|
||
| Completed |
NCT06113432 -
CPAP Therapy Through a Helmet or a Full Face Mask in Patients With Acute Hypoxemic Respiratory Failure: Cross-over Study
|
N/A | |
| Recruiting |
NCT05042063 -
Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease
|
||
| Recruiting |
NCT04615429 -
Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19
|
Phase 2 | |
| Completed |
NCT05047653 -
RALE Versus CORADS/CT-Severity Score in COVID-19
|
||
| Active, not recruiting |
NCT05047016 -
Study to Evaluate the Dynamic Consent Model Based on the Blockchain-based Clinical Trial Platform METORY
|
N/A | |
| Active, not recruiting |
NCT05033847 -
Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above
|
Phase 2 | |
| Recruiting |
NCT06113757 -
Investigation of Efficacy and Safety of Electrical Signal Therapy Provided by Dr Biolyse® Device in COVID-19 Disease
|
N/A | |
| Completed |
NCT05504655 -
N-Acetylcysteine as an Adjuvant Therapy in Critically Ill COVID-19 Patients:
|
||
| Active, not recruiting |
NCT05035524 -
A Randomized Controlled Trial to Investigate The Role of Adjuvant Inhalable Sodium Bicarbonate Solution 8.4% in Treatment of COVID-19
|
N/A | |
| Completed |
NCT05065879 -
Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes
|
Phase 4 | |
| Withdrawn |
NCT04390217 -
LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia
|
Phase 2 | |
| Withdrawn |
NCT04460105 -
Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia
|
Phase 1 | |
| Suspended |
NCT04901689 -
Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation
|
Phase 3 |